Comparing SG&A Expenses: Viatris Inc. vs Pharming Group N.V. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This chart offers a comparative analysis of Selling, General, and Administrative (SG&A) expenses for Viatris Inc. and Pharming Group N.V. from 2014 to 2023.

Viatris Inc.: A Steady Climb

Viatris Inc. has shown a consistent upward trend in SG&A expenses, peaking in 2023 with a 210% increase from 2014. This growth reflects the company's strategic investments in expanding its market reach and operational capabilities.

Pharming Group N.V.: A Volatile Journey

In contrast, Pharming Group N.V. experienced a more volatile trajectory, with expenses fluctuating significantly. Notably, 2022 marked a high point with a 3,160% increase from 2014, indicating a period of aggressive expansion or restructuring.

Insights and Implications

These trends highlight the differing strategic approaches of these companies, offering valuable insights for investors and industry analysts.